TS-065451 — The Need The need for effective vaccine development platforms has never been more pressing, especially in the face of evolving pathogens such as the measles virus. Current vaccine production methods often face challenges in achieving optimal expression levels and immunogenicity, hindering their eff…

TS-064189 — The Need The current global landscape demands innovative solutions to address the urgent need for a safe and efficacious SARS-CoV-2 vaccine, particularly for the vulnerable population of infants and children under 12 years old. Existing vaccines face challenges in terms of durability, cost, and sta…

TS-062682 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…

TS-062679 — Glioblastoma (GBM) is the most common malignant brain tumor accounting for 47.7% of all brain cancers. Unfortunately, treatments are limited, and survival is poor, with approximately 40% living the first-year post-diagnosis and 17% in the second year. The Need Oncolytic viruses (OVs) are a prom…

TS-062213 — The Need: Preventing Respiratory Syncytial Virus (RSV) Infection and Disease Respiratory Syncytial Virus (RSV) is a highly prevalent and dangerous pathogen responsible for significant morbidity and mortality, particularly in infants, young children, and immunocompromised individuals. Despite its gl…